Gates Package — page 731

AMa I > NIH/FIC) [E] >; Josh Daniel Hi Jennifer - can you let me know what days/times would work best for you to join a call with us? From: Ian Saunders Sent: Friday, May 19, 2017 9:03 AM To: Routh, Jennifer (NIH/NIAID) [E] @nih.gov>; Jen Krajicek @bgc3.com> Cc: Niranjan Bose @bgc3.com>; Eiss, Robert (NIH/FIC) [E] @mail.nih.gov>; Josh Daniel @bgc3.com> Subject: Re: Draft agenda for June 2 NIH-BMGF workshop Hi Jennifer - Very nice to meet you I would love to set a time to chat with you and our producer here in Bill's office (Jen Krajicek, cc'd here) so we can chat about how we might be able to figure out a way forward to lightly capture some footage of Bill's visit to NIH next month. Typically we have followed Bill on the "non-conference room" and "non-confidential" parts of his visits, capturing the learning he's doing. We also typically take 5-10 minutes at the end of the visit and have Bill stand outside or inside for a "stand up" interview where he runs over what he just saw. We'd love to chat with you about the best way to be unobtrusive followers on this upcoming trip. Jen can set up a call next week. Perhaps the three of chat together and report back to Bose and Robert what we end up deciding to do. Kind regards, Ian From: Niranjan Bose @bgc3.com> Date: Thursday, May 18, 2017 at 2:58 PM To: "Eiss, Robert (NIH/FIC) [E]" @mail.nih.gov> Cc: "Routh, Jennifer (NIH/NIAID) [E]" @nih.gov>, Ian Saunders @bgc3.com> Subject: RE: Draft agenda for June 2 NIH-BMGF workshop Dear Robert, Adding my colleague, Ian Saunders to the email thread, who will be able to work with Jennifer on the filming needs, etc. Your proposed split of 15 min and 45 min. sounds good to me. The elements of the tour outlined below are also good. As you outline your minute by minute, we would like to see the technical aspects that will be covered in the 45 min walking tour. I have heard a lot about the wonderful work at the VRC, so I am sure it will be tough to squeeze everything in within 45 min. we are excited about hearing more about the structure guided immunogen design work in the HIV, RSV, Flu and related areas. The RNA vaccine platforms work is also something that Bill is very keen to learn more about.